-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The research and development of new drugs is characterized by high risk, high difficulty, high cost and time-consuming
.
According to industry data, it took at least 10 years and an investment of US$1 billion for a new drug to be successfully developed in the past, but about 90% of drug candidates will fail at some stage of clinical trials, so there are great challenges in developing new drugs
.
The emergence of artificial intelligence (AI) has changed the process of traditional new drug research and development, which can greatly shorten the time of drug discovery, preclinical research, and clinical trials, and save the cost of compound screening and clinical trials
.
It can be said that AI technology is giving birth to a new revolution in the pharmaceutical field
.
Looking at the world, large multinational pharmaceutical companies, including Novartis, Pfizer, GSK, AstraZeneca, Sanofi, etc.
, have already tried to deploy AI to develop new drugs, and are in the AI pharmacy track
.
Among them, Sanofi has made frequent moves since the second half of 2021.
In November of that year, there were 2 related layouts in the AI field, including cooperating with Owkin to develop treatments for 4 specific types of cancer (non-small cell lung cancer, triple negative breast cancer, mesothelial tumor and multiple myeloma); access to Baidu mRNA sequence design algorithm (LinearDesign technology) for the design of vaccines and therapeutic products
.
In recent years, the domestic AI pharmaceutical track has gradually become more lively.
For example, many Internet technology companies have entered the market, including Huawei's establishment of the medical intelligence "EIHealth", Alibaba Cloud's cooperation with the Global Health Drug Research and Development Center, and Tencent's establishment of an AI-driven drug research and development platform.
"Yunshen Zhiyao", Baidu established Baitu Biotechnology, ByteDance established a department dedicated to big health business,
etc.
With the layout of these giant companies, the enthusiasm for research and development in the field of AI pharmacy has increased, and capital has also increased, and the investment quota has increased year by year, including Hengrui Medicine, WuXi AppTec and other large pharmaceutical companies.
Investment and other methods, and gradually cut into the field of AI pharmaceuticals
.
In 2022, the AI pharmaceutical track is still hot
.
For example, it was reported in early January that three large international pharmaceutical companies have reached cooperation
.
Absci announces a $610 million research collaboration with Merck
.
The two companies will leverage Absci's AI-driven drug innovation platform for drug development; Sanofi announced a research collaboration license agreement of up to $5.
2 billion with Exscientia, which will use Exscientia's end-to-end AI-driven personalized medicine platform, Co-development of up to 15 novel small molecule drug candidates in oncology and immunology; on January 6, Amgen announced a research collaboration agreement of over $1.
9 billion with Generate Biomedicines
.
The two parties will utilize the AI drug discovery technology platform developed by Generate to develop protein therapies for the top 5 clinical targets, involving multiple therapeutic areas and treatment modalities
.
Domestic pharmaceutical companies are also actively deploying the AI pharmaceutical track
.
On January 11, Fosun Pharma and Insilicon announced a "marriage".
The two parties will jointly promote the research and development of AI drugs for multiple targets on a global scale
.
According to the agreement, Insilicon will receive an upfront payment and milestone payments of US$13 million, and share the commercialization profits of the QPCTL project
.
In addition, Fosun Pharma will also provide equity investment to Insilicon
.
It is reported that this cooperation has also set a new high for domestic AI pharmaceutical down payment R&D cooperation
.
This also shows that the domestic recognition of AI pharmacy has been getting higher and higher, and it is expected that the AI pharmacy track will be extremely hot in 2022
.
.
According to industry data, it took at least 10 years and an investment of US$1 billion for a new drug to be successfully developed in the past, but about 90% of drug candidates will fail at some stage of clinical trials, so there are great challenges in developing new drugs
.
The emergence of artificial intelligence (AI) has changed the process of traditional new drug research and development, which can greatly shorten the time of drug discovery, preclinical research, and clinical trials, and save the cost of compound screening and clinical trials
.
It can be said that AI technology is giving birth to a new revolution in the pharmaceutical field
.
Looking at the world, large multinational pharmaceutical companies, including Novartis, Pfizer, GSK, AstraZeneca, Sanofi, etc.
, have already tried to deploy AI to develop new drugs, and are in the AI pharmacy track
.
Among them, Sanofi has made frequent moves since the second half of 2021.
In November of that year, there were 2 related layouts in the AI field, including cooperating with Owkin to develop treatments for 4 specific types of cancer (non-small cell lung cancer, triple negative breast cancer, mesothelial tumor and multiple myeloma); access to Baidu mRNA sequence design algorithm (LinearDesign technology) for the design of vaccines and therapeutic products
.
In recent years, the domestic AI pharmaceutical track has gradually become more lively.
For example, many Internet technology companies have entered the market, including Huawei's establishment of the medical intelligence "EIHealth", Alibaba Cloud's cooperation with the Global Health Drug Research and Development Center, and Tencent's establishment of an AI-driven drug research and development platform.
"Yunshen Zhiyao", Baidu established Baitu Biotechnology, ByteDance established a department dedicated to big health business,
etc.
With the layout of these giant companies, the enthusiasm for research and development in the field of AI pharmacy has increased, and capital has also increased, and the investment quota has increased year by year, including Hengrui Medicine, WuXi AppTec and other large pharmaceutical companies.
Investment and other methods, and gradually cut into the field of AI pharmaceuticals
.
In 2022, the AI pharmaceutical track is still hot
.
For example, it was reported in early January that three large international pharmaceutical companies have reached cooperation
.
Absci announces a $610 million research collaboration with Merck
.
The two companies will leverage Absci's AI-driven drug innovation platform for drug development; Sanofi announced a research collaboration license agreement of up to $5.
2 billion with Exscientia, which will use Exscientia's end-to-end AI-driven personalized medicine platform, Co-development of up to 15 novel small molecule drug candidates in oncology and immunology; on January 6, Amgen announced a research collaboration agreement of over $1.
9 billion with Generate Biomedicines
.
The two parties will utilize the AI drug discovery technology platform developed by Generate to develop protein therapies for the top 5 clinical targets, involving multiple therapeutic areas and treatment modalities
.
Domestic pharmaceutical companies are also actively deploying the AI pharmaceutical track
.
On January 11, Fosun Pharma and Insilicon announced a "marriage".
The two parties will jointly promote the research and development of AI drugs for multiple targets on a global scale
.
According to the agreement, Insilicon will receive an upfront payment and milestone payments of US$13 million, and share the commercialization profits of the QPCTL project
.
In addition, Fosun Pharma will also provide equity investment to Insilicon
.
It is reported that this cooperation has also set a new high for domestic AI pharmaceutical down payment R&D cooperation
.
This also shows that the domestic recognition of AI pharmacy has been getting higher and higher, and it is expected that the AI pharmacy track will be extremely hot in 2022
.
